

# Marc Blondel

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9525700/marc-blondel-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66  
papers

2,227  
citations

24  
h-index

45  
g-index

77  
ext. papers

2,559  
ext. citations

7.5  
avg, IF

4.22  
L-index

#	Paper	IF	Citations
66	Isolation of drugs active against mammalian prions using a yeast-based screening assay. <i>Nature Biotechnology</i> , <b>2003</b> , 21, 1075-81	44.5	154
65	Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. <i>Science</i> , <b>2003</b> , 302, 1208-12	33.3	139
64	The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. <i>EMBO Journal</i> , <b>2000</b> , 19, 5362-75	13	138
63	Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. <i>EMBO Journal</i> , <b>2000</b> , 19, 6085-97	13	102
62	Degradation of Hof1 by SCF(Grr1) is important for actomyosin contraction during cytokinesis in yeast. <i>EMBO Journal</i> , <b>2005</b> , 24, 1440-52	13	98
61	Guidelines and recommendations on yeast cell death nomenclature. <i>Microbial Cell</i> , <b>2018</b> , 5, 4-31	3.9	96
60	Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. <i>PLoS ONE</i> , <b>2008</b> , 3, e1981	3.7	90
59	Mitochondrial ATP synthase disorders: molecular mechanisms and the quest for curative therapeutic approaches. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2009</b> , 1793, 186-99	4.9	88
58	Yeast as a system for modeling mitochondrial disease mechanisms and discovering therapies. <i>DMM Disease Models and Mechanisms</i> , <b>2015</b> , 8, 509-26	4.1	83
57	Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. <i>Oncogene</i> , <b>2004</b> , 23, 4400-12	9.2	81
56	Nuclear export of Far1p in response to pheromones requires the export receptor Msn5p/Ste21p. <i>Genes and Development</i> , <b>1999</b> , 13, 2284-300	12.6	80
55	Cytotoxicity of diatom-derived oxylipins in organisms belonging to different phyla. <i>Journal of Experimental Biology</i> , <b>2004</b> , 207, 2935-46	3	76
54	A yeast-based assay identifies drugs active against human mitochondrial disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 11989-94	11.5	60
53	Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA. <i>Nature Communications</i> , <b>2017</b> , 8, 16043	17.4	58
52	Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. <i>PLoS ONE</i> , <b>2008</b> , 3, e2174	3.7	58
51	Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. <i>Biotechnology Journal</i> , <b>2007</b> , 2, 68-75	5.6	47
50	Consequences of the pathogenic T9176C mutation of human mitochondrial DNA on yeast mitochondrial ATP synthase. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , <b>2010</b> , 1797, 1105-12	4.6	43

49	A yeast-based assay to isolate drugs active against mammalian prions. <i>Methods</i> , <b>2006</b> , 39, 72-7	4.6	41
48	G2 cyclins are required for the degradation of G1 cyclins in yeast. <i>Nature</i> , <b>1996</b> , 384, 279-82	50.4	41
47	The importance of naturally attenuated SARS-CoV-2 in the fight against COVID-19. <i>Environmental Microbiology</i> , <b>2020</b> , 22, 1997-2000	5.2	35
46	Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. <i>EMBO Molecular Medicine</i> , <b>2011</b> , 3, 35-49	12	34
45	EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers. <i>Cancers</i> , <b>2018</b> , 10,	6.6	33
44	Using budding yeast to screen for anti-prion drugs. <i>Biotechnology Journal</i> , <b>2006</b> , 1, 58-67	5.6	28
43	The dominant-negative interplay between p53, p63 and p73: A family affair. <i>Oncotarget</i> , <b>2016</b> , 7, 69549-69564	6.9	27
42	Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost $\alpha$ -adrenergic receptor agonistic activity. <i>ACS Chemical Neuroscience</i> , <b>2014</b> , 5, 1075-82	5.7	22
41	The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 19081-9	5.4	22
40	Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers. <i>Journal of Pathology</i> , <b>2015</b> , 235, 334-41	9.4	21
39	The toll-like receptor agonist imiquimod is active against prions. <i>PLoS ONE</i> , <b>2013</b> , 8, e72112	3.7	21
38	Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a. <i>Human Molecular Genetics</i> , <b>2019</b> , 28, 1561-1577	5.6	21
37	Isolation and characterization of HRT1 using a genetic screen for mutants unable to degrade Gic2p in <i>Saccharomyces cerevisiae</i> . <i>Genetics</i> , <b>2000</b> , 155, 1033-44	4	20
36	Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. <i>Biochimie</i> , <b>2011</b> , 93, 1047-54	4.6	19
35	The various facets of the protein-folding activity of the ribosome. <i>Biotechnology Journal</i> , <b>2011</b> , 6, 668-735	5.6	19
34	Nuclear processing of nascent transcripts determines synthesis of full-length proteins and antigenic peptides. <i>Nucleic Acids Research</i> , <b>2019</b> , 47, 3086-3100	20.1	19
33	Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. <i>Nature Communications</i> , <b>2014</b> , 5, 5585	17.4	18
32	A single step synthesis of 6-aminophenanthridines from anilines and 2-chlorobenzonitriles. <i>Tetrahedron</i> , <b>2004</b> , 60, 4705-4708	2.4	18

31	Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 178, 13-29	6.8	17
30	Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation. <i>Scientific Reports</i> , <b>2016</b> , 6, 32117	4.9	15
29	Polyunsaturated fatty acids inhibit PI3K activity in a yeast-based model system. <i>Biotechnology Journal</i> , <b>2009</b> , 4, 1190-7	5.6	15
28	An expeditious synthesis of 6-aminophenanthridines. <i>Tetrahedron Letters</i> , <b>2005</b> , 46, 3725-3727	2	14
27	Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities. <i>PLoS ONE</i> , <b>2009</b> , 4, e7376	3.7	13
26	Guanabenz, an alpha2-selective adrenergic agonist, activates Ca <sup>2+</sup> -dependent chloride currents in cystic fibrosis human airway epithelial cells. <i>European Journal of Pharmacology</i> , <b>2008</b> , 592, 33-40	5.3	13
25	Antiprion drugs as chemical tools to uncover mechanisms of prion propagation. <i>Prion</i> , <b>2007</b> , 1, 48-52	2.3	13
24	Synthesis of conjugates of 6-aminophenanthridine and guanabenz, two structurally unrelated prion inhibitors, for the determination of their cellular targets by affinity chromatography. <i>Bioconjugate Chemistry</i> , <b>2010</b> , 21, 279-88	6.3	12
23	Tools for the study of ribosome-borne protein folding activity. <i>Biotechnology Journal</i> , <b>2008</b> , 3, 1033-40	5.6	12
22	A yeast model for the mechanism of the Epstein-Barr virus immune evasion identifies a new therapeutic target to interfere with the virus stealthiness. <i>Microbial Cell</i> , <b>2017</b> , 4, 305-307	3.9	12
21	In Cellulo Protein-mRNA Interaction Assay to Determine the Action of G-Quadruplex-Binding Molecules. <i>Molecules</i> , <b>2018</b> , 23,	4.8	12
20	A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus. <i>DMM Disease Models and Mechanisms</i> , <b>2014</b> , 7, 435-44	4.1	11
19	Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles. <i>European Journal of Medicinal Chemistry</i> , <b>2014</b> , 82, 363-71	6.8	10
18	The long-lasting love affair between the budding yeast <i>Saccharomyces cerevisiae</i> and the Epstein-Barr virus. <i>Biotechnology Journal</i> , <b>2015</b> , 10, 1670-81	5.6	10
17	p53, p63 and p73 in the wonderland of. <i>Oncotarget</i> , <b>2017</b> , 8, 57855-57869	3.3	10
16	Mechanism of cystathionine- $\beta$ -synthase inhibition by disulfiram: The role of bis(N,N-diethylthiocarbamate)-copper(II). <i>Biochemical Pharmacology</i> , <b>2020</b> , 182, 114267	6	10
15	Using yeast to model calcium-related diseases: example of the Hailey-Hailey disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2014</b> , 1843, 2315-21	4.9	8
14	Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models. <i>Infectious Disorders - Drug Targets</i> , <b>2009</b> , 9, 31-9	1.1	8

13	The double life of the ribosome: When its protein folding activity supports prion propagation. <i>Prion</i> , <b>2017</b> , 11, 89-97	2.3	7
12	A yeast-based screening assay identifies repurposed drugs that suppress mitochondrial fusion and mtDNA maintenance defects. <i>DMM Disease Models and Mechanisms</i> , <b>2019</b> , 12,	4.1	6
11	Long-Term Fipronil Treatment Induces Hyperactivity in Female Mice. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	6
10	Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast <i>bcs1</i> mutants. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2017</b> , 1864, 2297-2307	4.9	6
9	Artemisinin and its derivatives target mitochondrial c-type cytochromes in yeast and human cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118661	4.9	5
8	Evaluation of CDK Inhibitor Selectivity. <i>Enzyme Inhibitors Series</i> , <b>2006</b> , 103-119		5
7	Sneaking Out for Happy Hour: Yeast-Based Approaches to Explore and Modulate Immune Response and Immune Evasion. <i>Genes</i> , <b>2019</b> , 10,	4.2	4
6	Flirting with CFTR modifier genes at happy hour. <i>Genome Medicine</i> , <b>2012</b> , 4, 98	14.4	3
5	The different activities of RNA G-quadruplex structures are controlled by flanking sequences. <i>Life Science Alliance</i> , <b>2022</b> , 5,	5.8	3
4	An Overview of In Vivo and In Vitro Models for Autosomal Dominant Polycystic Kidney Disease: A Journey from 3D-Cysts to Mini-Pigs. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
3	Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation. <i>Neurotherapeutics</i> , <b>2021</b> , 18, 1137-1150	6.4	2
2	Quadruplex-interacting compounds for regulating the translation of the EpsteinBarr virus nuclear antigen 1 (EBNA1) mRNA: A new strategy to prevent and treat EBV-related cancers. <i>Annual Reports in Medicinal Chemistry</i> , <b>2020</b> , 243-286	1.6	1
1	Meeting report: 3(rd) Meeting of the Biosensor Workgroup of the GDR2588. <i>Biotechnology Journal</i> , <b>2014</b> , 9, 178-9	5.6	